News ArchivesRead News
Schwarz Pharma’s Parkinson’s disease patch receives green light recommendation
Wednesday November 22, 2006
11.17.2006(Forbes) - Schwarz Pharma AG said it has received a recommendation to extend the marketing authorisation of its Neupro patch to treat Parkinson’s disease from the European Committee for Medical Products for Human Use (CHMP).
Upon receipt of approval, Schwarz Pharma will able to market Neupro as a combined therapy for patients with advanced Parkinson’s disease throughout all 25 European countries.
Neupro is already approved and on the European market as a monotherapy treatment for patients with early stage Parkinson’s disease.
Recent NewsFeb 20 - February 20, 2018 News Update
Feb 13 - February 13, 2018 News Update
Feb 6 - February 6, 2018 News Update
Jan 30 - January 30, 2018 News Update
Jan 23 - January 23, 2018 News Update
Jan 16 - January 16, 2018 News Update
Jan 9 - January 9, 2018 News Update
Jan 2 - January 2, 2018 News Update
Dec 26 - December 26, 2017 News Update
Dec 19 - December 19, 2017 News Update
Dec 8 - New technique scours the genome for genes that combat disease
Dec 8 - Restless sleep may be an early sign of Parkinson's, dementia
Dec 1 - Defects in cell's 'waste disposal system' linked to Parkinson's
Dec 1 - Dual virtual reality/treadmill exercises promote brain plasticity in Parkinson's patients
Nov 17 - 'Moving Day' participant is not letting young-onset Parkinson's disease stop him
Nov 17 - Focused ultrasound shows promise for treating Parkinson's tremor
Nov 17 - New research to target air pollution as a potential trigger for Parkinson’s
Nov 17 - This device will let you feel what it's like to suffer from Parkinson's
Nov 10 - How does Parkinson's disease influence depression?
Nov 10 - House votes to repeal ObamaCare's Medicare cost-cutting board